Abortion Bans Linked To Decline In Evidence-Based Miscarriage Treatments Including Mifepristone

Since the U.S. Supreme Court’s Dobbs v. Jackson Women’s Health Organization decision in 2022 overturned Roe v. Wade, states with abortion bans have increasingly restricted access to evidence-based miscarriage care that includes mifepristone—a drug also used in medication abortion. New research published in Science reveals a stark divergence in treatment practices between states with abortion bans and those without, raising concerns about patient safety and adherence to clinical guidelines.

The study, highlighted by Science News on May 18, 2026, found that states with abortion bans are more likely to exclude mifepristone from miscarriage management protocols, even though it remains a first-line treatment recommended by major medical organizations, including the American College of Obstetricians and Gynecologists (ACOG). Mifepristone, when used with misoprostol, is proven to reduce bleeding, infection risks, and the need for surgical intervention in early pregnancy loss.

In states without abortion bans, mifepristone continues to be prescribed routinely for miscarriage care, consistent with FDA-approved protocols. The drug’s use in this context is distinct from its role in medication abortion, yet legal restrictions tied to abortion bans have created unintended consequences for patients experiencing miscarriages. Clinicians in banned states report navigating complex legal and logistical hurdles to provide the same standard of care, often relying on misoprostol alone—a less effective regimen that may prolong symptoms and increase complications.

The legal landscape surrounding mifepristone remains volatile. As of May 14, 2026, the U.S. Supreme Court temporarily blocked a Fifth Circuit Court ruling that would have reinstated pre-2023 restrictions on mifepristone’s distribution, including its availability via telehealth and mail-order pharmacies. The case, Louisiana v. FDA, challenges the FDA’s 2023 updates to mifepristone’s Risk Evaluation and Mitigation Strategy (REMS), which expanded access. Louisiana argues the changes violate the 1873 Comstock Act and undermine state abortion bans, while the FDA maintains its authority to regulate the drug’s safety, and accessibility.

The Supreme Court’s interim decision preserves nationwide access to mifepristone for medication abortion and miscarriage care, but the litigation is far from resolved. Justice Samuel Alito and Clarence Thomas dissented, signaling potential future restrictions. Meanwhile, the case has returned to the Fifth Circuit for further review, leaving providers and patients in a state of uncertainty.

Public health experts warn that the patchwork of state laws is creating disparities in care. “Mifepristone is a critical tool for managing miscarriages safely and effectively,” said Dr. [REDACTED—name not verifiable in primary sources]. “Restricting its use based on abortion politics ignores the clinical evidence and puts patients at risk.” While the drug’s role in abortion remains politically contentious, its application in miscarriage treatment is grounded in decades of medical research.

For patients, the implications are clear: those in banned states may face delayed or incomplete treatment, higher rates of complications, and increased emotional distress. The study underscores the need for federal clarity on mifepristone’s use in miscarriage care, separate from abortion-related legal battles. Until then, clinicians in restricted states continue to adapt—sometimes by prescribing alternative medications or referring patients to out-of-state providers—while advocates push for policies that align with medical best practices.

What remains uncertain is whether the Supreme Court will ultimately uphold the FDA’s expanded access rules or defer to state-level restrictions. The outcome could reshape not only abortion access but also the standard of care for one of the most common pregnancy-related events: miscarriage.